ResearcherRoswell Park Comprehensive Cancer CenterNo recent work listed

Xiang Ling

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-1587-8315; OpenAlex author ID A5029609547. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 2

FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras agai… Co-author DOI 10.1002/ctm2.881 ↗
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. Co-author DOI 10.1186/s13046-018-0899-8 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Fengzhi Li · 2 shared papers, 2018–2022 · strength 0.24
- Paper FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to cont… DOI 10.1002/ctm2.881 ↗
- Paper An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment res… DOI 10.1186/s13046-018-0899-8 ↗
Christos K Fountzilas · 1 shared paper, 2022 · strength 0.16
- Paper FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to cont… DOI 10.1002/ctm2.881 ↗
Xinjiang Wang · 1 shared paper, 2018 · strength 0.08
- Paper An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment res… DOI 10.1186/s13046-018-0899-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.